New Drugs Get "Luck Of The Draw" In FDA's First Round Of 18-Month Reviews
"We're not being surprised by anything we are seeing" in the initial batch of FDAAA-mandated post-market assessments, FDA's Boucher says.
"We're not being surprised by anything we are seeing" in the initial batch of FDAAA-mandated post-market assessments, FDA's Boucher says.